Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 in Squamous Cell Lung Carcinoma
NCT02920476Phase 2Completed
- Sponsor
- University of Florida
- Start
- Jul 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trifluridine + tipiracil in squamous cell carcinoma of the lung (SCCL), sponsored by University of Florida. Primary endpoints: Objective Response Rate at 1 year and Progression-Free Survival at 1 year. Started Jul 2017; status: completed.
02
Drugs
trifluridine + tipiracil
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT02920476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02920476.